World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
20 December 2018
Melanoma Institute Australia (MIA) is proud to have one of the world’s leading pathologists, Associate Professor Michael Tetzlaff, with us for this past week.
A/Prof Tetzlaff hails from the Department of Pathology and Translational and Molecular Pathology at the MD Anderson Cancer Centre at The University of Texas.
Spending his time with fellow pathologist Professor Richard Scolyer, MIA’s Co-Medical Director, and his team at Royal Prince Alfred Hospital, A/Prof Tetzlaff is sharing his pathological expertise in primary mucosal melanoma and merkel cell carcinoma, and assisting in the assessment of pathological samples from patients undergoing neoadjuvant, targeted therapy.
Among over 100 published peer-reviewed articles, A/Prof Tetzlaff is also lead author on a paper recently published by the International Neoadjuvant Melanoma Consortium that aims to standardise the pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy.
It is an honour to have Associate Professor Tetzlaff as an international collaborator, and we are delighted to be hosting him on his first ever trip to Australia.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients